Unknown

Dataset Information

0

Comparative cost-effectiveness of Option B+ for prevention of mother-to-child transmission of HIV in Malawi.


ABSTRACT: To estimate the cost-effectiveness of prevention of mother-to-child transmission (MTCT) of HIV with lifelong antiretroviral therapy (ART) for pregnant and breastfeeding women ('Option B+') compared with ART during pregnancy or breastfeeding only unless clinically indicated ('Option B').Mathematical modelling study of first and second pregnancy, informed by data from the Malawi Option B+ programme.Individual-based simulation model. We simulated cohorts of 10?000 women and their infants during two subsequent pregnancies, including the breastfeeding period, with either Option B+ or B. We parameterized the model with data from the literature and by analysing programmatic data. We compared total costs of antenatal and postnatal care, and lifetime costs and disability-adjusted life-years of the infected infants between Option B+ and Option B.During the first pregnancy, 15% of the infants born to HIV-infected mothers acquired the infection. With Option B+, 39% of the women were on ART at the beginning of the second pregnancy, compared with 18% with Option B. For second pregnancies, the rates MTCT were 11.3% with Option B+ and 12.3% with Option B. The incremental cost-effectiveness ratio comparing the two options ranged between about US$ 500 and US$ 1300 per DALY averted.Option B+ prevents more vertical transmissions of HIV than Option B, mainly because more women are already on ART at the beginning of the next pregnancy. Option B+ is a cost-effective strategy for PMTCT if the total future costs and lost lifetime of the infected infants are taken into account.

SUBMITTER: Tweya H 

PROVIDER: S-EPMC5359470 | biostudies-literature | 2016 Mar

REPOSITORIES: biostudies-literature

altmetric image

Publications

Comparative cost-effectiveness of Option B+ for prevention of mother-to-child transmission of HIV in Malawi.

Tweya Hannock H   Keiser Olivia O   Haas Andreas D AD   Tenthani Lyson L   Phiri Sam S   Egger Matthias M   Estill Janne J  

AIDS (London, England) 20160301 6


<h4>Objective</h4>To estimate the cost-effectiveness of prevention of mother-to-child transmission (MTCT) of HIV with lifelong antiretroviral therapy (ART) for pregnant and breastfeeding women ('Option B+') compared with ART during pregnancy or breastfeeding only unless clinically indicated ('Option B').<h4>Design</h4>Mathematical modelling study of first and second pregnancy, informed by data from the Malawi Option B+ programme.<h4>Methods</h4>Individual-based simulation model. We simulated coh  ...[more]

Similar Datasets

| S-EPMC6560771 | biostudies-literature
| S-EPMC3540037 | biostudies-literature
| S-EPMC7568211 | biostudies-literature
| S-EPMC5507522 | biostudies-literature
| S-EPMC7948351 | biostudies-literature
| S-EPMC4226974 | biostudies-literature
| S-EPMC4422229 | biostudies-literature
| S-EPMC2873795 | biostudies-literature
| S-EPMC3045936 | biostudies-other
| S-EPMC4527770 | biostudies-literature